FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558358143> ?p ?o ?g. }

• W2558358143 abstract "Abstract Abstract 3105 Introduction: relapse after ASCT remains the most important cause of treatment failure among high-risk lymphomas. In order to improve outcome, allogeneic hematopoietic stem cell transplantation (AlloSCT) is used to exploit graft-versus-lymphoma (GVL) effect; on the other hand, feasibility of AlloSCT is limited by the high risk of infections and graft-versus-host disease (GvHD), accounting for transplant-related mortality (TRM) up to 40% in some circumstances. Patients and Methods: we retrospectively analyzed data on 34 high-risk NHL patients who underwent ASCT followed closely by reduced-intensity AlloSCT (“tandem auto-allo”) from January 2002 to November 2010. The tandem transplantation decision relied on the high-risk disease, needing some consolidation therapy after ASCT, and on the hypothesis of a high GVL effect when a significant cytoreduction occurred after AlloSCT. The search for an allogeneic donor was started at the beginning of salvage regimen. Preparative regimen for reduced-intensity AlloSCT was an association of fludarabine-busulfan-ATG or fludarabine-cyclophosphamide with our without thiotepa. In one patient conditioning was BEAM regimen. GvHD prophylaxis included cyclosporine alone or in combination with methotrexate. Results: median patients' age at AlloSCT was 47 (27–68); hystotypes were as follows: diffuse large B-cell n= 5, follicular n= 14, transformed follicular n= 4, mantle-cell n= 5, lymphoplasmocytic lymphoma n=1, anaplastic large T-cell n= 2, peripheral T-cell n= 3. Donor were HLA-identical sibling (n= 29) or 10/10-matched unrelated (n=5). Peripheral stem cell was used in all patients but one. Median interval between ASCT and AlloSCT was 76 days (36–197). Median prior therapeutic lines before tandem transplantation were 2 (0–4). Overall, 16 patients were in complete remission, 13 were in partial remission and five were in progressive disease at time of AlloSCT. Successful allogeneic engraftment occurred in all patients. At a median follow-up of 46 (8–108) months since AlloSCT, 5-year overall survival (OS) is 77% (61–93) and progression-free survival (PFS) is 68% (51–85) (figure 1). Disease relapse or progression occurred in six patients (18%), 100-day TRM was 0%, overall TRM rate was 9%. Causes of TRM were: infection in two patients and severe extensive chronic GvHD in one patient. Ten patients developed grade >=2 acute GvHD and fifteen patients chronic GvHD, respectively. Conclusions: tandem transplantation is feasible in relapsed or refractory NHL patients having a HLA-identical allogeneic stem cell donor, with 0% early TRM and 9% overall TRM rate. This tandem approach, i.e. disease debulking by salvage therapy and ASCT followed by allogeneic GVL immunotherapy, could represent a suitable therapeutic option for those patients. This invites promptly starting a donor search in these situations. Disclosures: No relevant conflicts of interest to declare." @default.
• W2558358143 created "2016-12-08" @default.
• W2558358143 creator A5000359788 @default.
• W2558358143 creator A5001266472 @default.
• W2558358143 creator A5003722893 @default.
• W2558358143 creator A5017049071 @default.
• W2558358143 creator A5021060422 @default.
• W2558358143 creator A5021277803 @default.
• W2558358143 creator A5021944572 @default.
• W2558358143 creator A5022161221 @default.
• W2558358143 creator A5024161871 @default.
• W2558358143 creator A5045261121 @default.
• W2558358143 creator A5045967298 @default.
• W2558358143 creator A5059804319 @default.
• W2558358143 creator A5072246038 @default.
• W2558358143 creator A5075546030 @default.
• W2558358143 creator A5082045927 @default.
• W2558358143 creator A5085831038 @default.
• W2558358143 date "2011-11-18" @default.
• W2558358143 modified "2023-10-01" @default.
• W2558358143 title "Autologous Transplantation Followed by Reduced-Intensity Allogeneic Transplantation Is Feasible in Patients with High-Risk Non-Hodgkin's Lymphoma" @default.
• W2558358143 doi "https://doi.org/10.1182/blood.v118.21.3105.3105" @default.
• W2558358143 hasPublicationYear "2011" @default.
• W2558358143 type Work @default.
• W2558358143 sameAs 2558358143 @default.
• W2558358143 citedByCount "0" @default.
• W2558358143 crossrefType "journal-article" @default.
• W2558358143 hasAuthorship W2558358143A5000359788 @default.
• W2558358143 hasAuthorship W2558358143A5001266472 @default.
• W2558358143 hasAuthorship W2558358143A5003722893 @default.
• W2558358143 hasAuthorship W2558358143A5017049071 @default.
• W2558358143 hasAuthorship W2558358143A5021060422 @default.
• W2558358143 hasAuthorship W2558358143A5021277803 @default.
• W2558358143 hasAuthorship W2558358143A5021944572 @default.
• W2558358143 hasAuthorship W2558358143A5022161221 @default.
• W2558358143 hasAuthorship W2558358143A5024161871 @default.
• W2558358143 hasAuthorship W2558358143A5045261121 @default.
• W2558358143 hasAuthorship W2558358143A5045967298 @default.
• W2558358143 hasAuthorship W2558358143A5059804319 @default.
• W2558358143 hasAuthorship W2558358143A5072246038 @default.
• W2558358143 hasAuthorship W2558358143A5075546030 @default.
• W2558358143 hasAuthorship W2558358143A5082045927 @default.
• W2558358143 hasAuthorship W2558358143A5085831038 @default.
• W2558358143 hasConcept C126322002 @default.
• W2558358143 hasConcept C141071460 @default.
• W2558358143 hasConcept C143998085 @default.
• W2558358143 hasConcept C2776694085 @default.
• W2558358143 hasConcept C2776755627 @default.
• W2558358143 hasConcept C2777058707 @default.
• W2558358143 hasConcept C2777408962 @default.
• W2558358143 hasConcept C2777525834 @default.
• W2558358143 hasConcept C2779263901 @default.
• W2558358143 hasConcept C2779338263 @default.
• W2558358143 hasConcept C2779695342 @default.
• W2558358143 hasConcept C2779968505 @default.
• W2558358143 hasConcept C2780611847 @default.
• W2558358143 hasConcept C2780775027 @default.
• W2558358143 hasConcept C2911091166 @default.
• W2558358143 hasConcept C71924100 @default.
• W2558358143 hasConceptScore W2558358143C126322002 @default.
• W2558358143 hasConceptScore W2558358143C141071460 @default.
• W2558358143 hasConceptScore W2558358143C143998085 @default.
• W2558358143 hasConceptScore W2558358143C2776694085 @default.
• W2558358143 hasConceptScore W2558358143C2776755627 @default.
• W2558358143 hasConceptScore W2558358143C2777058707 @default.
• W2558358143 hasConceptScore W2558358143C2777408962 @default.
• W2558358143 hasConceptScore W2558358143C2777525834 @default.
• W2558358143 hasConceptScore W2558358143C2779263901 @default.
• W2558358143 hasConceptScore W2558358143C2779338263 @default.
• W2558358143 hasConceptScore W2558358143C2779695342 @default.
• W2558358143 hasConceptScore W2558358143C2779968505 @default.
• W2558358143 hasConceptScore W2558358143C2780611847 @default.
• W2558358143 hasConceptScore W2558358143C2780775027 @default.
• W2558358143 hasConceptScore W2558358143C2911091166 @default.
• W2558358143 hasConceptScore W2558358143C71924100 @default.
• W2558358143 hasLocation W25583581431 @default.
• W2558358143 hasOpenAccess W2558358143 @default.
• W2558358143 hasPrimaryLocation W25583581431 @default.
• W2558358143 hasRelatedWork W1964856016 @default.
• W2558358143 hasRelatedWork W1980994809 @default.
• W2558358143 hasRelatedWork W2007220641 @default.
• W2558358143 hasRelatedWork W2048005105 @default.
• W2558358143 hasRelatedWork W2061325374 @default.
• W2558358143 hasRelatedWork W2076153347 @default.
• W2558358143 hasRelatedWork W2085459287 @default.
• W2558358143 hasRelatedWork W2091865970 @default.
• W2558358143 hasRelatedWork W2132589242 @default.
• W2558358143 hasRelatedWork W2282100889 @default.
• W2558358143 hasRelatedWork W2327695677 @default.
• W2558358143 hasRelatedWork W2537162292 @default.
• W2558358143 hasRelatedWork W2577233371 @default.
• W2558358143 hasRelatedWork W2583242044 @default.
• W2558358143 hasRelatedWork W2917857663 @default.
• W2558358143 hasRelatedWork W2979350016 @default.
• W2558358143 hasRelatedWork W3016413043 @default.
• W2558358143 hasRelatedWork W3029550323 @default.
• W2558358143 hasRelatedWork W3032251843 @default.
• W2558358143 hasRelatedWork W2739425605 @default.
• W2558358143 isParatext "false" @default.
• W2558358143 isRetracted "false" @default.

• next